MX2010009843A - Conjugados antagonistas peptidicos analogos a la bombesina. - Google Patents

Conjugados antagonistas peptidicos analogos a la bombesina.

Info

Publication number
MX2010009843A
MX2010009843A MX2010009843A MX2010009843A MX2010009843A MX 2010009843 A MX2010009843 A MX 2010009843A MX 2010009843 A MX2010009843 A MX 2010009843A MX 2010009843 A MX2010009843 A MX 2010009843A MX 2010009843 A MX2010009843 A MX 2010009843A
Authority
MX
Mexico
Prior art keywords
peptide antagonist
analog peptide
bombesin analog
antagonist conjugates
integer
Prior art date
Application number
MX2010009843A
Other languages
English (en)
Inventor
Maecke Helmut
Claude Reubi Jean
Mansi Rosalba
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39677415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010009843(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Basel filed Critical Univ Basel
Publication of MX2010009843A publication Critical patent/MX2010009843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un medicamento de diagnóstico y terapéutico que comprende un conjugado antagonista peptídico análogo a la bombesina que tiene la fórmula general (1), donde A es un quelante de metales que comprende al menos un radionucleido metálico, es un separador unido al extremo N de C o un enlace covalente y C es un antagonista peptídico análogo a la bombesina que tiene una secuencia como la reivindicada, donde además x es un numero entero entre 1 y 3 y n es un numero entero entre 1 y 6.
MX2010009843A 2008-03-07 2009-02-27 Conjugados antagonistas peptidicos analogos a la bombesina. MX2010009843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075180A EP2100900A1 (en) 2008-03-07 2008-03-07 Bombesin analog peptide antagonist conjugates
PCT/EP2009/001403 WO2009109332A1 (en) 2008-03-07 2009-02-27 Bombesin analog peptide antagonist conjugates

Publications (1)

Publication Number Publication Date
MX2010009843A true MX2010009843A (es) 2011-03-04

Family

ID=39677415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009843A MX2010009843A (es) 2008-03-07 2009-02-27 Conjugados antagonistas peptidicos analogos a la bombesina.

Country Status (32)

Country Link
US (2) US9035023B2 (es)
EP (2) EP2100900A1 (es)
JP (1) JP5784911B2 (es)
KR (2) KR101734553B1 (es)
CN (1) CN101965358B (es)
AR (1) AR070809A1 (es)
AU (1) AU2009221204C1 (es)
BR (1) BRPI0909823B1 (es)
CA (1) CA2717427C (es)
CL (1) CL2009000537A1 (es)
CO (1) CO6290707A2 (es)
CR (1) CR11671A (es)
CY (1) CY1118687T1 (es)
DK (1) DK2252628T3 (es)
DO (1) DOP2010000269A (es)
EC (1) ECSP10010467A (es)
ES (1) ES2615805T3 (es)
HU (1) HUE032980T2 (es)
MX (1) MX2010009843A (es)
NZ (1) NZ587795A (es)
PA (1) PA8818501A1 (es)
PE (1) PE20091753A1 (es)
PL (1) PL2252628T3 (es)
PT (1) PT2252628T (es)
RU (1) RU2523531C2 (es)
SI (1) SI2252628T1 (es)
SV (1) SV2010003660A (es)
TW (1) TWI515011B (es)
UA (1) UA103314C2 (es)
UY (1) UY31693A (es)
WO (1) WO2009109332A1 (es)
ZA (1) ZA201006385B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
MX2013005697A (es) * 2010-11-22 2014-08-01 Piramal Imaging Sa Analogos de bombesina marcados con lutecio 177, para radioterapia.
WO2012156511A1 (en) * 2011-05-19 2012-11-22 Universitätsspital Basel Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
EP2900279B1 (en) 2012-09-25 2019-08-14 Advanced Accelerator Applications USA, Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
US10137212B2 (en) 2013-03-13 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
WO2015119763A1 (en) * 2014-02-06 2015-08-13 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
PL3152226T3 (pl) 2014-06-06 2019-10-31 Univ Muenchen Tech Modyfikowane cyklopentapeptydy i ich zastosowania
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
WO2015192211A1 (en) 2014-06-16 2015-12-23 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
CN104610431B (zh) * 2014-11-26 2017-12-15 南京市第一医院 一种多肽及其应用
WO2017106798A2 (en) 2015-12-16 2017-06-22 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
US11241511B2 (en) 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
WO2018132751A1 (en) 2017-01-12 2018-07-19 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
EP3880691A4 (en) * 2018-11-13 2022-09-21 Provincial Health Services Authority RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF THE GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISEASES
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CA3145872A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
IL293008A (en) * 2019-12-19 2022-07-01 Univ Muenchen Tech Modified peptides that are antagonistic to grpr for cancer imaging and therapy
WO2021250240A1 (en) 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP3973999A1 (en) 2020-09-28 2022-03-30 Orano Med Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
AR128023A1 (es) 2021-12-17 2024-03-20 3B Pharmaceuticals Gmbh Ligandos de anhidrasa carbónica ix
WO2024052431A1 (en) 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
DE69018226T2 (de) * 1989-07-20 1995-09-21 Sandoz Ag Markierte polypeptidderivate.
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
EP0977579B1 (en) 1997-04-22 2009-03-11 Curator Of The University Of Missouri Gastrin receptor-avid peptide conjugates
CA2346154A1 (en) 2001-05-02 2002-11-02 University Of Missouri Gastrin receptor-avid peptide conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
TR200002402T2 (tr) 1997-12-24 2001-01-22 Vertex Pharmaceuticals Incorporated Aspartil proteaz inhibitörü ön-ilaçlar.
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
IL155773A0 (en) * 2000-12-20 2003-12-23 Warner Lambert Co Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
RU2006105644A (ru) * 2003-07-24 2006-08-10 Бракко Имэджинг С.П.А. (It) Стабильные радиофармацевтические композиции и способы их получения
US20090062509A1 (en) 2006-03-16 2009-03-05 Aldo Cagnolini Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
MX2013005697A (es) * 2010-11-22 2014-08-01 Piramal Imaging Sa Analogos de bombesina marcados con lutecio 177, para radioterapia.

Also Published As

Publication number Publication date
ZA201006385B (en) 2016-10-26
CA2717427A1 (en) 2009-09-11
KR20110014565A (ko) 2011-02-11
PT2252628T (pt) 2017-02-10
WO2009109332A1 (en) 2009-09-11
KR20160128425A (ko) 2016-11-07
SV2010003660A (es) 2011-02-17
AR070809A1 (es) 2010-05-05
BRPI0909823A2 (pt) 2019-03-06
JP2011515338A (ja) 2011-05-19
CA2717427C (en) 2016-02-23
AU2009221204A1 (en) 2009-09-11
CN101965358A (zh) 2011-02-02
ECSP10010467A (es) 2010-10-30
AU2009221204C1 (en) 2016-12-08
EP2100900A1 (en) 2009-09-16
US9035023B2 (en) 2015-05-19
PL2252628T3 (pl) 2017-07-31
CR11671A (es) 2010-11-01
HUE032980T2 (en) 2017-11-28
CY1118687T1 (el) 2017-07-12
TW200944239A (en) 2009-11-01
US20150265733A1 (en) 2015-09-24
DK2252628T3 (en) 2017-02-06
EP2252628B1 (en) 2016-12-28
KR101734553B1 (ko) 2017-05-11
TWI515011B (zh) 2016-01-01
BRPI0909823B1 (pt) 2022-04-19
CO6290707A2 (es) 2011-06-20
DOP2010000269A (es) 2010-10-31
UY31693A (es) 2010-01-05
PA8818501A1 (es) 2010-04-21
UA103314C2 (ru) 2013-10-10
CL2009000537A1 (es) 2010-07-19
JP5784911B2 (ja) 2015-09-24
NZ587795A (en) 2012-07-27
US20110097266A1 (en) 2011-04-28
AU2009221204B2 (en) 2013-09-05
EP2252628A1 (en) 2010-11-24
RU2010140846A (ru) 2012-04-20
SI2252628T1 (sl) 2017-05-31
RU2523531C2 (ru) 2014-07-20
PE20091753A1 (es) 2009-12-13
CN101965358B (zh) 2019-09-03
ES2615805T3 (es) 2017-06-08

Similar Documents

Publication Publication Date Title
MX2010009843A (es) Conjugados antagonistas peptidicos analogos a la bombesina.
NZ604718A (en) Human antibody drug conjugates against tissue factor
MX2011005963A (es) Conjugados de neurotensina o analogos de neurotensina y sus usos.
MX2011005964A (es) Conjugados terapeuticos de peptidos y sus usos.
MX2011005965A (es) Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
MY188455A (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
MY169432A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
NZ630888A (en) Antibody drug conjugate (adc) purification
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY157239A (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ599791A (en) Therapeutic peptides
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
BR112012011328A2 (pt) inibidores de akt
TNSN08321A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
WO2007106544A3 (en) Chelating conjugates having a substituted aromatic moiety and derivatives thereof
MY151973A (en) Cyclic depsipeptides
CY1109685T1 (el) Χρησιμοποιηση συμπλοκων ενωσεων σιδηρου(ιιι)
MX2009001578A (es) Lactamas terapeuticas.
NZ610740A (en) 177lutetium-labeled bombesin analogs for radiotherapy
GB2453402A (en) Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof
MX2011007108A (es) Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos.
IL198202A0 (en) Peptide-cytotoxic conjugates
AU2019257492A1 (en) Novel compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal